Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD

Diabetes

Volumn 65, Issue 8, 2016, Pages 2187-2200

  Softic, Samir ^a,b   Boucher, Jeremie ^a   Solheim, Marie H ^a,c   Fujisaka, Shiho ^a   Haering, Max Felix ^a   Homan, Erica P ^a   Winnay, Jonathon ^a   Perez Atayde, Antonio R ^b   Kahn, C Ronald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBROBLAST GROWTH FACTOR 21; GLUCAGON; GLUCOSE; GLYCOLYTIC ENZYME; INSULIN RECEPTOR; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; GLYCOGEN; SOMATOMEDIN C;

ADIPOSE TISSUE; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FATTY LIVER; GENE EXPRESSION; GENE INACTIVATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEPATITIS; HEPATOMEGALY; HISTOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; KETOGENESIS; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIPID STORAGE; LIPODYSTROPHY; LIPOTOXICITY; LIVER FIBROSIS; LIVER INJURY; LIVER TUMOR; LIVER WEIGHT; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; GENETICS; GLUCOSE TOLERANCE TEST; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID DIET; LIVER; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; GLYCOGEN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; LIPODYSTROPHY; LIVER; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTOR, INSULIN;

EID: 84980332386     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0213     Document Type: Article

References (40)

1. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 2003;100:15712-15717
2. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998;12:3168-3181
3. Pajvani UB, Trujillo ME, Combs TP, et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005;11:797-803
4. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998;12: 3182-3194
5. Chalasani N, Younossi Z, Lavine JE, et al.; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-1609
6. Gorden P, Lupsa BC, Chong AY, Lungu AO. Is there a human model for the 'metabolic syndrome' with a defined aetiology? Diabetologia 2010;53:1534-1536
7. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87: 2395
8. Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013;59:131-137
9. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003;26:30-35
10. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109: 1345-1350
11. Robbins DC, Sims EA. Recurrent ketoacidosis in acquired, total lipodystrophy (lipoatrophic diabetes). Diabetes Care 1984;7:381-385
12. Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010;24:2629-2637
13. Spolcová A, Holubová M, Mikulášková B, et al. Changes in FGF21 serum concentrations and liver mRNA expression in an experimental model of complete lipodystrophy and insulin-resistant diabetes. Physiol Res 2014;63:483-490
14. Cauble MS, Gilroy R, Sorrell MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001;71:892-895
15. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41:753-760
16. Schneeweiss B, Pammer J, Ratheiser K, et al. Energy metabolism in acute hepatic failure. Gastroenterology 1993;105:1515-1521
17. Boucher J, Softic S, El Ouaamari A, et al. Differential roles of insulin and IGF-1 receptors in adipose tissue development and function. Diabetes 2016;65: 2201-2213
18. Boucher J, Mori MA, Lee KY, et al. Impaired thermogenesis and adipose tissue development in mice with fat-specific disruption of insulin and IGF-1 signalling. Nat Commun 2012;3:902
19. Debosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J Biol Chem 2014;289:10989-10998
20. O'Neill BT, Lauritzen HP, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Reports 2015;11:1220-1235
21. Eguchi J, Wang X, Yu S, et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab 2011;13:249-259
22. Mannaerts I, Schroyen B, Verhulst S, et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration. PLoS One 2013;8:e84071
23. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004;35:196-199
24. Carter-Kent C, Brunt EM, Yerian LM, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;52:190-197
25. Soli AH, Kahn CR, Neville DM Jr, Roth J. Insulin receptor deficiency in genetic and acquired obesity. J Clin Invest 1975;56:769-780
26. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010;207:245-255
27. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011;7:137-150
28. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113: 1774-1783
29. Blüher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002;3:25-38
30. Nakayama H, Otabe S, Ueno T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 2007;56:470-475
31. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003;82:129-146
32. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845
33. Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012;96:727-734
34. van Wissen J, Bakker N, Doodeman HJ, Jansma EP, Bonjer HJ, Houdijk AP. Preoperative methods to reduce liver volume in bariatric surgery: a systematic review. Obes Surg 2016;26:251-256
35. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-1560
36. Murata Y, Konishi M, Itoh N. FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J Nutr Metab 2011;2011:981315
37. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5:415-425
38. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-437
39. Iqbal MA, Siddiqui FA, Gupta V, et al. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer 2013;12:72
40. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321